PCI Biotech (Norway) Management Evaluation
| PCIB Stock | NOK 1.33 0.07 5.56% |
PCI Biotech employs about 14 people. The company is managed by 4 executives with a total tenure of roughly 12 years, averaging almost 3.0 years of service per executive, having 3.5 employees per reported executive. Inspection of PCI Biotech's management performance can provide insight into the company performance.
| Ronny Skuggedal CEO CEO CFO |
PCI |
PCI Biotech Management Team Effectiveness
The company has return on total asset (ROA) of (0.3973) % which means that it has lost $0.3973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7359) %, meaning that it generated substantial loss on money invested by shareholders. PCI Biotech's management efficiency ratios could be used to measure how well PCI Biotech manages its routine affairs as well as how well it operates its assets and liabilities.PCI Biotech Workforce Comparison
PCI Biotech Holding is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 6,068. PCI Biotech adds roughly 14.0 in number of employees claiming only tiny portion of equities under Health Care industry.
PCI Biotech Holding Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. PCI Biotech Holding Price Series Summation is a cross summation of PCI Biotech price series and its benchmark/peer.
PCI Biotech Notable Stakeholders
A PCI Biotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as PCI Biotech often face trade-offs trying to please all of them. PCI Biotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting PCI Biotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Ronny Skuggedal | CEO CFO | Profile | |
| Lucy Wabakken | Acting CDO | Profile | |
| Anders Hgset | Chief Officer | Profile | |
| Kristin Eivindvik | Chief Officer | Profile |
About PCI Biotech Management Performance
The success or failure of an entity such as PCI Biotech Holding often depends on how effective the management is. PCI Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of PCI management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the PCI management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization technology platform. PCI Biotech Holding ASA was founded in 2000 and is headquartered in Oslo, Norway. PCI BIOTECH operates under Pharmaceuticals And Biosciences classification in Norway and is traded on Oslo Stock Exchange. It employs 11 people.
PCI Biotech Workforce Analysis
Traditionally, organizations such as PCI Biotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare PCI Biotech within its industry.PCI Biotech Manpower Efficiency
Return on PCI Biotech Manpower
| Revenue Per Employee | 448.1K | |
| Revenue Per Executive | 1.6M | |
| Net Loss Per Employee | 6.3M | |
| Net Loss Per Executive | 22.1M | |
| Working Capital Per Employee | 2.7M | |
| Working Capital Per Executive | 9.5M |
Other Information on Investing in PCI Stock
PCI Biotech financial ratios help investors to determine whether PCI Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PCI with respect to the benefits of owning PCI Biotech security.